Scandinavian ChemoTech receives new approval in Japan for its TSE for deep seated tumours

Scandinavian ChemoTech has received the final approval for its DEEPC patent application in Japan. The patent protects the innovation used for the TSE therapy in deep seated tumours and secondary bone cancer.

The approval is considered by ChemoTech to be of significant importance for future negations with potential industrial partners as Japan is an important market for the Company´s clinical project regarding deep seated tumours.

"Obtaining this approval for this innovation in Japan is very important for the continued protection of our TSE platform and makes it more interesting for industrial partners to start a dialogue with us as we continue to make progress in our deep seated clinical project"  - says Mohan Frick CEO and co-founder of ChemoTech.

The concept of TSE is to establish a better balance between necrosis and apoptosis by enhancing the uptake of chemotherapy and avoiding unwanted destruction that can generate inflammation, which is of great importance when treating sensitive tissue and organs.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.